This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
Checkpoint immunotherapies have helped many patients by enabling their immune cells to stay active against cancer. Checkpoint immunotherapies can sometimes reinvigorate “exhausted” cells, but not always. Dr. Abdel Hakeem wants to understand what controls this exhaustion, specifically at the epigenetic level (where genes are turned on/off). Using a viral model called LCMV, he’s exploring epigenetic patterns associated with exhaustion that might suggest other ways to prevent and reverse it. These strategies might also work well with current checkpoint therapies and help provide patients with even better outcomes.
University of Pennsylvania School of Medicine | All Cancers, Lung Cancer, Melanoma | 2016 | E. John Wherry, Ph.D.
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
This October for Liver Cancer Awareness Month, let’s delve into new treatments, research insights, and how we are fueling a future immune to liver cancer.
This October for Breast Cancer Awareness Month, learn about new treatments, research discoveries, and our impact on a future immune to breast cancer.